FDA-Approved Pancreatic Cancer Breakthrough Faces Access Barriers

A new drug called daraxonrasib has received FDA approval for pancreatic cancer — a disease that has long defied meaningful therapeutic progress — offering patients with specific tumor mutations a genuine chance at extended survival. Yet the distance between regulatory approval and a patient's ability to receive treatment has proven vast, as insurance structures, prior authorization requirements, and pricing realities conspire to delay or deny access. This moment illuminates a recurring tension in modern medicine: the gap between what science can now accomplish and what the systems surrounding